8 May 2020
12 March 2020
[Name and contact details redacted]
REQUEST FOR INFORMATION
Thank you for your email of 17 February 2020. You have asked if there have been any supply constraints for cladribine and dacarbazine in the past three years.
In early 2018, a manufacturing delay resulted in stocks of dacarbazine 200mg for injection being unavailable. This was resolved by the end of April 2018. An alternative supply of the pharmaceutical was obtained during this period to ensure that stocks were still available for patients.
Cladribine injection has had no stock limitations over the last few years.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Policy Manager, Engagement and Implementation
Last updated: 7 May 2020